Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Supplementary Materials Consolidated Financial Statements for the three months ended March 31, 2026 (IFRS)
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the three months ended March 31, 2026)
Determination of Details Regarding Share Acquisition Associated with the Introduction of the Trust-Based Stock Compensation System
F. Hoffmann-La Roche Announces First Quarter Sales 2026
Corporate Governance Report
[Delayed] Matters Concerning Controlling Shareholder, Etc.
Position and Policy Regarding Reduction of the Investment Unit
Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy
Notice of Distribution of Retained Earnings
CONSOLIDATED FINANCIAL STATEMENTS (IFRS)(Non-Audited)(for the year ended December 31, 2025)
Supplementary Materials Consolidated Financial Statements for the year ended December 31, 2025 (IFRS)
Revision of the Stock Compensation System
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2025
[Update on Disclosed Matter] Notice Concerning Completion of Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary and an Absorption-Type Merger
Corporate Governance Report
Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron
Notice of Absorption-Type Merger of a Wholly-Owned Subsidiary, Renalys Pharma, Inc.
Notice Concerning Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2025 (IFRS)
CONSOLIDATED FINANCIAL STATEMENTS(IFRS)(Non-Audited)(for the nine months ended September 30, 2025)